Vitamin K3 (a Siah2 inhibitor) improves the chemosensitivity of CML cells in the HME via targeted inhibition of the Siah2-PHD3-HIF-1α-VEGF axis.127. This evidence concerns the gene HIF1A and chronic myelogenous leukemia, BCR-ABL1 positive.